QbD Group
    The EU Commission Proposes a General Reform of Pharmaceutical Legislation – What it Means for Patients and the Industry

    The EU Commission Proposes a General Reform of Pharmaceutical Legislation – What it Means for Patients and the Industry

    The EU Commission is proposing a general reform of pharmaceutical legislation. Read more about what this means for patients and the industry.

    May 5, 20231 min read

    Regulatory Affairs plays a key role in the pharmaceutical industry: from drug development to commercialization. QbD's regulatory team supports clients with large and small molecule products and the more complex ATMPs of both innovative and generic drug manufacturers to ensure that their medicinal product dossier is compiled with great accuracy and registrations are submitted and followed until the end of the procedure. Need support?

    About the Author

    Koen Laenen
    Koen Laenen

    RA Manager Pharma at QbD Group

    Koen manages the Regulatory Affairs Pharma team at QbD Group, guiding pharmaceutical companies through regulatory submissions and lifecycle management.

    Regulatory Affairs services

    Navigate Regulatory Complexity with Confidence

    Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.

    Read more
    Share this article

    Subscribe to the latest updates in life science

    Expert perspectives delivered to your inbox — pick your interests.

    No spam, ever. Unsubscribe anytime.

    Keep reading

    Related articles

    We use cookies to enhance your experience

    We use essential cookies for site functionality and optional analytics cookies to improve our services. Read our Privacy Policy and Cookie Policy.